Glioblastoma (GBM) is the most aggressive, deadliest, and most common brain malignancy
in adults. Despite the advances made in surgical techniques, radiotherapy and …

Glioblastoma (GBM) is a particularly devastating tumor with a median survival of about 16
months. Recent research has revealed novel insights into the outstanding heterogeneity of …

Treatment of adult brain tumors, in particular glioblastoma, remains a significant clinical
challenge, despite modest advances in surgical technique, radiation, and …

Glioblastoma multiforme is the most common and lethal primary malignant brain tumor.
Although considerable progress has been made in technical proficiencies of surgical and …

Malignant gliomas are devastating tumours that frequently kill patients within 1 year of
diagnosis. The major obstacle to a cure is diffuse invasion, which enables tumours to …

The invasive capacity of GBM is one of the key tumoral features associated with treatment
resistance, recurrence, and poor overall survival. The molecular machinery underlying GBM …

Simple Summary The estimated survival time for glioblastoma patients is extremely low; only
about 5% of patients survive five years post diagnosis. The standard of care for glioblastoma …

Gliomas are the most common intracranial tumors in humans. The most malignant among
these tumors is glioblastoma (GBM), with an incidence of 3–5 out of 100,000 persons in …

Gliomas are the most common intracranial tumors. In the US, approximately 15,000 patients
die with glioblastoma per year (CBTRUS 2002). Despite modern diagnostics and treatments …

Despite advances in surgical and medical therapy, glioblastoma consistently remains a fatal
disease. Over the last 20 years, no significant increase in survival has been achieved for …